Introduction: Barrett’s esophagus (BE) is a premalignant condition characterized by replacement of the normal squamous epithelium of the distal esophagus with specialized columnar epithelium, most commonly because of chronic gastroesophageal reflux (1). BE increases the risk of developing Barrett’s esophageal adenocarcinoma (BEA), a malignancy that

Introduction: Barrett’s esophagus (BE) is a premalignant condition in which normal squamous epithelium of the distal esophagus is replaced by specialized intestinal-type columnar epithelium (1). It develops most commonly in the setting of chronic gastroesophageal reflux disease (GERD) and represents the principal precursor lesion for esophageal ade

Introduction: Barrett’s esophagus (BE) is a premalignant condition in which the normal squamous lining of the distal esophagus is replaced by columnar epithelium (1). It is the only known precursor to esophageal adenocarcinoma (EAC), a malignancy whose incidence has risen steadily over recent decades (1). Although BE provides an opportunity for ear

As we transition into 2026, Medsynapse recognizes that the most significant advancements in healthcare are born from collective expertise. Medical progress is not merely an individual pursuit; it is a testament to the shared intellect, unwavering resilience, and profound professional advocacy that defines our community. Behind every clinical breakt

Introduction Acute pancreatitis (AP) is an inflammatory disease of the pancreas caused by premature activation of pancreatic enzymes, frequently leading to hospitalization and, in severe cases, multiple organ dysfunction. Standard management includes fluid resuscitation, enzyme inhibitors, proton pump inhibitors, and supportive care. However, treat

Gastroenterology in 2025 entered a new phase of targeted and metabolic care. IL-23 inhibitors expanded treatment sequencing in inflammatory bowel disease, while the first approved therapy for MASH shifted hepatology from surveillance to active intervention. Alongside these advances, AI-enabled pathology began reshaping how liver disease therapies a

Introduction Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, arising predominantly from the interstitial cells of Cajal (ICC) (1–4). The majority of GISTs are driven by gain-of-function mutations in KIT or PDGFRA receptor tyrosine kinases, making them uniquely responsive to targeted ther

Introduction: Acute severe ulcerative colitis (ASUC) is a serious and potentially life-threatening flare of ulcerative colitis (UC) (1). It presents with frequent bloody stools, abdominal pain, and signs of systemic inflammation (1). Standard treatment includes high-dose intravenous steroids, and if these fail, biologic agents such as infliximab ar

Introduction: Ulcerative Colitis (UC) is a chronic inflammatory disorder of the colon and rectum, characterized by continuous mucosal inflammation (1). It typically begins in the rectum and extends proximally in a uniform pattern (1). The disease imposes a substantial burden on patients, often causing persistent symptoms, frequent flares, hospitali